As of September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A carries a market capitalization of 4.12B, placing it among publicly traded companies globally. Its enterprise value stands at 3.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.12B |
| Enterprise Value | 3.05B |
JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A's next confirmed earnings release is scheduled for March 18, 2027.
| Earnings Date | 3/18/2027 |
As of September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A has 153.40M shares outstanding.
| Shares Outstanding | 153.40M |
As of September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A trades at a trailing price-to-earnings ratio of 13.14. The price-to-sales ratio is 1.32, and the price-to-book ratio stands at 1.49.
| PE Ratio | 13.14 |
| PS Ratio | 1.32 |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.54 |
As of September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A trades at an EV/EBITDA multiple of 8.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.54 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.05B versus a market cap of 4.12B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.98 |
| EV / EBITDA | 8.54 |
| EV / EBIT | 8.54 |
As of September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.35, indicating elevated leverage, while an interest coverage ratio of 34.41 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.69 |
| Quick Ratio | 0.72 |
| Debt / Equity | 3.35 |
| Debt / EBITDA | 0.26 |
| Interest Coverage | 34.41 |
Over the twelve months ended September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A posted a return on equity (ROE) of 11.85, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.31 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.05, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.49, useful for judging operating efficiency across full business cycles. The company generates approximately 1.38M in revenue per employee across its workforce of 2,257.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.35 indicates how many times JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 11.85 |
| Return on Assets (ROA) | 7.05 |
| Return on Invested Capital (ROIC) | 11.31 |
| Return on Capital Employed (ROCE) | 11.49 |
| Revenue Per Employee | 1.38M |
| Employee Count | 2,257.00 |
| Inventory Turnover | 4.35 |
Over the twelve months ended September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A recorded 36.59M in income tax expense. That works out to an effective tax rate of 10.35, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 353.57M, leaving 312.40M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 36.59M |
| Effective Tax Rate | 10.35 |
As of the close on November 17, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A's stock has declined approximately 31.04% over the past 52 weeks. The 50-day moving average sits at 27.22, while the 200-day moving average is 29.90.
| 52-Week Price Change | -31.04% |
| 50-Day Moving Average | 27.22 |
| 200-Day Moving Average | 29.90 |
Over the twelve months ended September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A generated 3.12B in revenue and converted that into 312.40M in net income, yielding earnings per share of 2.07. EBITDA reached 356.60M, while operating income came in at 310.21M.
| Revenue | 3.12B |
| Gross Profit | 1.84B |
| Operating Income | 310.21M |
| Pretax Income | 353.57M |
| Net Income | 312.40M |
| EBITDA | 356.60M |
| EBIT | 356.60M |
| Earnings Per Share (EPS) | 2.07 |
As of September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A holds 1.19B in cash and equivalents against 92.98M in total debt, resulting in a net debt position of -163.84M. Total book value stands at 2.76B, with working capital of 1.14B providing operational flexibility.
| Cash & Cash Equivalents | 1.19B |
| Total Debt | 92.98M |
| Net Debt | -163.84M |
| Equity (Book Value) | 2.76B |
| Book Value Per Share | 17.97 |
| Working Capital | 1.14B |
These figures cover the twelve months ended September 30, 2026.
| Capital Expenditures | -104.18M |
Over the twelve months ended September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A posted a gross margin of 58.92, reflecting its pricing power and cost economics. The operating margin of 9.96 and net profit margin of 10.03 provide insight into operational efficiency.
| Gross Margin | 58.92 |
| Operating Margin | 9.96 |
| Pretax Margin | 11.35 |
| Profit Margin | 10.03 |
| EBITDA Margin | 11.45 |
Over the twelve months ended September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A paid dividends of 0.91 per share. The dividend payout ratio of 43.40 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A shareholders.
| Dividend Per Share | 0.91 |
| Payout Ratio | 43.40 |
| Shareholder Yield | 4.36 |
JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A's most recent stock split took place on July 12, 2006 with a 1:2 split ratio.
| Last Split Date | 7/12/2006 |
| Split Ratio | 1:2 |
As of September 30, 2026, JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A has an Altman Z-Score of 3.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.24 |
Already premium?